Latest Breaking News On - Company to accelerate development - Page 1 : comparemela.com

BEACON Trial of BEAM-101 in Sickle Cell Disease Progressing with Consented Patients Projected to Fill Sentinel Cohort and to Initiate Expansion Cohort First Patient Consented in Phase 1/2 Trial of.

North carolinaUnited statesUnited kingdomJohn evansDan budwickDavid liuChelcie listerMitchell weissProgram nowJude children research hospitalCompany to accelerate developmentExchange commissionBeam therapeutics incStrategic communicationsResearch development rd expensesSickle cell disease progressing